My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 707

    1.

    Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

    Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

    Harder H, Nielsen L, Tu DT, Astrup A.

    Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

    Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

    Diabet Med. 2005 Aug;22(8):1016-23.PMID: 16026367 [PubMed - indexed for MEDLINE]Related articles

    4.

    Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

    Seino Y, Rasmussen MF, Zdravkovic M, Kaku K.

    Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. Epub 2008 May 20.PMID: 18495285 [PubMed - indexed for MEDLINE]Related articles

    5.

    One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

    Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

    Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.

    Diabetes Care. 2009 Jul;32(7):1224-30. Epub 2009 Mar 16.PMID: 19289857 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Luis Bautista J, Bugos C, Dirnberger G, Atherton T.

    Clin Ther. 2003 Jan;25(1):194-209.PMID: 12637120 [PubMed - indexed for MEDLINE]Related articles

    8.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    9.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    11.

    Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

    Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

    Lancet. 2009 Jul 4;374(9683):39-47. Epub 2009 Jun 8.PMID: 19515413 [PubMed - indexed for MEDLINE]Related articles

    12.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

    Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

    13.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    14.

    Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

    Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.

    Diabet Med. 2009 Mar;26(3):268-78.PMID: 19317822 [PubMed - indexed for MEDLINE]Related articles

    15.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    16.

    Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

    Nauck M, Marre M.

    Postgrad Med. 2009 May;121(3):5-15.PMID: 19491535 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

    Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group.

    Lancet. 2009 Feb 7;373(9662):473-81. Epub 2008 Sep 24.PMID: 18819705 [PubMed - indexed for MEDLINE]Related articles

    18.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    19.

    Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

    Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.

    Clin Ther. 2007 Jan;29(1):74-83.PMID: 17379048 [PubMed - indexed for MEDLINE]Related articles

    20.

    Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

    Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

    Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.PMID: 17559733 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity